ArticleCureus2026
Idiopathic Hypoparathyroidism in an Osteoporosis Patient Receiving Denosumab Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic hypoparathyroidism is a rare endocrine disorder characterized by impaired parathyroid hormone (PTH) secretion leading to hypocalcemia and hyperphosphatemia. We report the case of a 71-year-old female patient receiving denosumab for osteoporosis who was found to have asymptomatic hypocalcemia prior to her fifth denosumab injection. Lab results revealed a low ionized calcium level of 4.45 mg/dL, a low normal total calcium level of 8.2 mg/dL, and an inappropriately low PTH level of 17 pg/mL, with normal magnesium and vitamin D levels. Calcium levels were normal during the previous four doses. With no history of neck surgery, renal disease, autoimmune disease, or malabsorption, a diagnosis of idiopathic hypoparathyroidism was supported, likely unmasked by denosumab-associated suppression of bone resorption. Denosumab treatment was withheld, and calcium carbonate and calcitriol supplementation led to stabilization of serum calcium in the low-normal range, but PTH levels remained suppressed. Our case highlights the importance of ensuring normal calcium levels before denosumab administration and emphasizes the challenges of osteoporosis management in patients with hypoparathyroidism. In this area of treatment, evidence-based data remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.